Pets at Home vs Vroom

Pets Foundation celebrates 20 years of helping pets and the people who love them

Pets at Home's corporate foundation is celebrating 20 years of helping pets and the people who love them...

8-K Financial Filing Analysis for Pets at Home (2026-09-17)

PetMed Express, Inc. announced the appointment of Jeffrey Allen Willard as Chief Executive Officer, President, and Director, effective September 28, 2026. Mr. Willard succeeds Leslie C.G. Campbell, who had been serving as Interim CEO and President since August 2025 and is stepping down from both roles and the Board to pursue retirement. Mr. Willard brings executive leadership and e-commerce experience from previous leadership roles at Stewart MacDonald, Casper Sleep, and Healthy Lifestyle Brands. In addition, the Board appointed independent director Justin Mennen as the new Board Chair, concurrently eliminating the Lead Independent Director role.

• Jeffrey Allen Willard appointed CEO, President, and Director effective September 28, 2026, receiving a base salary of $550,000, a $120,000 signing bonus, and a target performance bonus of 75% of base salary.
• Inducement equity awards include 250,000 restricted stock units vesting over 3 years and up to 250,000 performance stock units tied to 3-year relative TSR vs. S&P 600 Specialty Retail Index, plus future annual LTI targets of $750,000.
• Interim CEO and Board Chair Leslie C.G. Campbell is resigning effective September 28, 2026; independent director Justin Mennen has been elected as the new Chair of the Board.

8-K Financial Filing Analysis for Pets at Home (2026-09-21)

On September 15, 2026, PetMed Express, Inc. appointed Tamar Elkeles, Ph.D., to its Board of Directors, effective September 17, 2026. In conjunction with her appointment, the Board expanded its size to five members. Dr. Elkeles qualifies as an independent director under Nasdaq listing standards and will serve on both the Compensation and Human Capital Committee and the Corporate Governance and Nominating Committee until the 2027 annual meeting of shareholders. With over 30 years of experience in organizational psychology, human capital leadership, and corporate governance across public and private tech companies, Dr. Elkeles is expected to strengthen PetMed's talent strategy, operational execution, and governance oversight.

• Dr. Tamar Elkeles appointed to the Board of Directors effective September 17, 2026, expanding the Board to 5 members.
• Dr. Elkeles will serve on the Compensation and Human Capital Committee and the Corporate Governance and Nominating Committee until the 2027 annual meeting.
• Compensation will follow the standard Non-Employee Director Compensation Program, alongside a standard director indemnification agreement.

8-K Financial Filing Analysis for Vroom (2026-09-30)

On September 30, 2026, Vroom, Inc. entered into a material financing agreement through its subsidiary, Vroom Automotive, LLC. The subsidiary issued 16,000 Series A1 preferred units and 4,000 Series B1 preferred units to SPE Holdings 2026-1 for aggregate gross proceeds of $20.0 million. The preferred units feature floating quarterly distributions linked to the 90-day average SOFR plus spreads of 8.50% (Series A1) and 9.25% (Series B1). Series B1 units are convertible into common units of Vroom Automotive at the holder's option. Vroom intends to allocate the proceeds toward debt repayment and acquiring residual interests in asset-backed securitization (ABS) trusts, supporting its restructured auto finance and analytics operations.

• Vroom Automotive issued 16,000 Series A1 and 4,000 Series B1 preferred units for aggregate gross proceeds of $20,000,000 on September 30, 2026.
• Quarterly variable distributions are set at 90-day average SOFR + 8.50% for Series A1 and SOFR + 9.25% for Series B1, with Series B1 holding convertible rights into common units.
• Proceeds are designated to repay outstanding obligations and purchase residual interests in asset-backed securitization (ABS) trusts.